Grifols publishes Q3 2026 earnings call transcript
GRFS•Grifols reported quarterly adjusted EBITDA of EUR 538 million and maintained its full-year adjusted EBITDA margin target of 25%. Management said Biopharma growth should moderate in the fourth quarter and expects no update on a potential US Biopharma IPO until 2027.
1. Quarterly results and outlook
Grifols' November 2 earnings call featured CEO Nacho Abia, CFO Rahul Srinivasan and investor relations head Daniel Segarra. Management maintained its full-year adjusted EBITDA margin target of 25% after quarterly adjusted EBITDA reached EUR 538 million. Biopharma growth should moderate in the fourth quarter, reflecting sales timing benefits and a strong year-earlier comparison.
2. China and IPO assessment
Management said China's albumin recovery is taking longer than expected, with elevated inventories continuing to pressure sales despite early improvement in end-market demand. Srinivasan expects no update on a potential US Biopharma IPO until 2027, while the board continues its assessment.
